# OnCo record paper-keynote-042-lancet-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-042-lancet-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-042-lancet-2019" ;
  schema:name "Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial"@en ;
  schema:description "Published report from the KEYNOTE-042 trial registered as NCT02220894, in The Lancet (2019), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-042-lancet-2019/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(18)32409-7>, <https://pubmed.ncbi.nlm.nih.gov/30955977/>, <https://europepmc.org/article/MED/30955977>, <https://clinicaltrials.gov/study/NCT02220894> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(18)32409-7> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Mok TSK, Wu YL, Kudaba I, et al." ;
  onco:trials <https://onco.cc/trials/keynote-042/> ;
  onco:journals <https://onco.cc/journals/lancet/> .